TITLE

Pharmaceutical Product Development

AUTHOR(S)
Stone, Andy
PUB. DATE
January 2007
SOURCE
Forbes Asia;1/29/2007, Vol. 3 Issue 2, p53
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This article profiles Pharmaceutical Product Development Inc. as one of the best managed companies in the U.S. based on the selection by editors. Hungry entrepreneurialism has turned the company into one of the largest and leanest providers of clinical trial services to the drug and biotech industries. Credit should be given to Chief Executive Fredric Eshelman, who's run the $3.9 billion company during its entire 21-year history.
ACCESSION #
23925623

 

Related Articles

  • PPD.  // Pharmaceutical Technology;Dec2009 Corporate Capabilities Supp, p142 

    A company profile of Pharmaceutical Product Development Inc. (PPD), a leading global research organization (CRO) in Wilmington, North Carolina, is presented. An overview of the company is given, along with contact information, number of employees, and date founded. It provides discovery,...

  • Sex drug and rocky road ahead for research firm. Williams, C.C. // Business North Carolina;Nov99, Vol. 19 Issue 11, p20 

    Forecasts the financial indicators for Pharmaceutical Product Development Inc. Judgment of Wall Street; Effort by United States drug companies on research and development; Losses at its research division.

  • Drug companies seek remedy for their ailing stock prices.  // Business North Carolina;Feb2000, Vol. 20 Issue 2, p85 

    Looks at the performance of the pharmaceutical industry in North Carolina in 1999. Revenue gains posted by contract-research organizations in the first half of 1999; Stock performance of the companies such as Quintiles Transnational Corp.; and Pharmaceutical Product Development Inc.; Sales of...

  • M& A Skills Take General Counsel To The Next Level. Carlton, A.P. // Corporate Legal Times;Nov2003, Vol. 13 Issue 144, p64 

    Interviews Fred Davenport Jr., president of Pharmaceutical Product Development Inc. on his rise through the corporate ranks in the company, in the U.S. Expansion of his staff in the legal department; Role of Davenport in the success of the company; Qualifications to become senior management...

  • PPD LICENSES GGTASE INHIBITOR COMPOUNDS TO DUKE UNIVERSITY.  // Biotech Business;Aug2005, Vol. 18 Issue 8, p1 

    Reports on an agreement signed by biotechnology company PPD Inc. with the Duke University in Durham, North Carolina in 2005. Duration of the development of the geranylgeranyl transferase inhibitor compounds by researchers at the university, according to the agreement; Views of PPD CEO Fred...

  • New member profiles.  // Australasian Biotechnology;Oct2013, Vol. 23 Issue 3, p66 

    The article profiles several companies, organizations, and universities that are members of the biotechnological industry. The members include the medical device and service solutions provider Coloplast Pty. Ltd., the global contract research organization Pharmaceutical Product Development...

  • Slow progress prods PPD to depart project.  // Business North Carolina;Aug2009, Vol. 29 Issue 8, p30 

    The article reports on the decision of Fred Eshelman, chief executive officer (CEO) of Pharmaceutical Product Development Inc. (PPD), pullout the company from the North Carolina Research Campus project. PPD has elected to terminate its lease in the 160,000 square-foot building due to slow...

  • Business News.  // Applied Clinical Trials;Apr2002, Vol. 11 Issue 4, p75 

    Reports developments in the pharmaceutical industry in the U.S. as of March 2002. Release of the supply management system, Clinicopia Suite by InfoPro Solutions; Automation of the Crohn's Disease Activity Index by CB Technologies Inc.; Acquisition of Medical research Laboratories International...

  • Here's to a Strong 2006. Miller, Jim // Pharmaceutical Technology;Jan2006, Vol. 30 Issue 1, p96 

    The article focuses on the pharmaceutical industry. One of the brightest spots in the clinical CRO business has been PPD Inc. The company is forecasting 18% revenue growth for 2006, enabling it to join Quintiles and Coyance as CROs with more than $1-billion revenues. It is opined that probably...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics